Transl Clin Pharmacol.  2021 Dec;29(4):226-238. 10.12793/tcp.2021.29.e21.

Determination of candesartan or olmesartan in hypertensive patient plasma using UPLC-MS/MS

• Jeong HC
• Seo YH
• Gu N
• Rhee MY
• Shin KH

• KMID: 2525623
• DOI: http://doi.org/10.12793/tcp.2021.29.e21

Abstract

Candesartan and olmesartan are angiotensin II receptor blockers (ARBs) used for the treatment of hypertension and heart failure. Quantitation methods for candesartan and olmesartan were developed using ultra-high performance liquid chromatography-tandem mass spectrometry following protein precipitation. Candesartan was separated using 5 mM ammonium formate (A) and 100% acetonitrile (B) and olmesartan was separated using 2 mM ammonium formate with 0.1% formic acid (A) and 100% acetonitrile (B). Separation was performed using an isocratic method with a Thermo hypersil GOLD C18 column. Electrospray ionization was used for analyte ionization and detection of candesartan, olmesartan, and the internal standards by multiple reaction monitoring. Developed method showed excellent linearity (r > 0.99) in the concentration range of 2–500 ng/mL for candesartan and 5–2,500 ng/mL for olmesartan. were 86.70–108.8% for candesartan and 87.87–112.6% for olmesartan. These methods were able to successfully measure plasma candesartan or olmesartan concentrations in hypertensive patients. This study can be used for pharmacokinetic studies of candesartan or olmesartan in humans.

Keyword

Candesartan; Olmesartan; Angiotensin II Receptor Blockers; Liquid Chromatography; Mass Spectrometry